Oddo BHF Asset Management SAS
1,883,387
2.25%
27,686
3.11%
04/30/2018
Norges Bank Investment Management
1,136,950
1.36%
-484,274
0.03%
12/31/2017
BNP Paribas Asset Management France SAS
933,334
1.11%
-7,630
0.26%
07/31/2018
The Vanguard Group, Inc.
914,062
1.09%
13,329
0.01%
07/31/2018
Amundi Asset Management SA (Investment Management)
823,549
0.98%
-166,727
0.23%
08/29/2018
OppenheimerFunds, Inc.
582,830
0.7%
0
0.06%
02/28/2018
BlackRock Fund Advisors
552,758
0.66%
5,504
0.01%
09/06/2018
BFT Investment Managers SA
377,921
0.45%
94,000
1.36%
01/31/2018
Columbia Wanger Asset Management LLC
291,000
0.35%
0
0.43%
03/29/2018
Fidelity Management & Research Co.
282,597
0.34%
-3,245
0.01%
07/31/2018
| Address |
65, quai Georges Gorse
Boulogne-Billancourt Ile-de-France 92650
France
|
|
Employees
|
- |
| Website |
http://www.ipsen.com |
| Updated |
07/08/2019 |
| Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. |
